Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label Phase II Clinical Trial: Evaluating the Safety and Efficacy of a Single Dose of CS-101 Injection in Participants With β-thalassemia Major

NCT07489196 is registered in ClinicalTrials.gov with CorrectSequence Therapeutics Co., Ltd as lead sponsor.

NCT NCT07489196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07489196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label Phase II Clinical Trial: Evaluating the Safety and Efficacy of a Single Dose of CS-101 Injection in Participants With β-thalassemia Major
Lead sponsor
CorrectSequence Therapeutics Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 5, 2026
Completion date
July 31, 2028
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

β-thalassemia major